创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology Luminex Platform: A New Driving Force for Drug Development

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-06-28 14:59
  • Views:

(Summary description)In the vast world of pharmaceutical R&D, technological innovation is the core driving force for scientific progress. By virtue of its Luminex platform, InnoModels Biotechnology has demonstrated significant advantages in the field of drug discovery and development, providing strong technical support for new drug discovery and development. In this article, we will introduce the advantages of Luminex platform and discuss its important role in drug discovery.

InnoModels Biotechnology Luminex Platform: A New Driving Force for Drug Development

(Summary description)In the vast world of pharmaceutical R&D, technological innovation is the core driving force for scientific progress. By virtue of its Luminex platform, InnoModels Biotechnology has demonstrated significant advantages in the field of drug discovery and development, providing strong technical support for new drug discovery and development. In this article, we will introduce the advantages of Luminex platform and discuss its important role in drug discovery.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-06-28 14:59
  • Views:
Information

In the vast world of pharmaceutical R&D, technological innovation is the core driving force for scientific progress. By virtue of its Luminex platform, InnoModels Biotechnology has demonstrated significant advantages in the field of drug discovery and development, providing strong technical support for new drug discovery and development. In this article, we will introduce the advantages of Luminex platform and discuss its important role in drug discovery.
Technical advantages of Luminex platform:
1. High-throughput detection capability: With its unique multi-detection technology, the Luminex platform is capable of detecting multiple biomarkers at the same time, realizing high-throughput sample processing. This advantage is especially critical in drug discovery and development, as it accelerates the drug screening process and improves R&D efficiency.
2. High sensitivity: The Luminex platform is extremely sensitive and can accurately measure biomarkers at very low concentrations. This is important for studying the mechanism of action of drugs in organisms, evaluating drug efficacy, and monitoring adverse drug reactions.
3. Low sample requirements: The Luminex platform requires a very small sample size to perform multiple assays, which is a huge advantage for drug discovery and development that values sample resources. At the same time, it also reduces the difficulty and cost of sample collection and improves the feasibility of experiments.
4. High degree of automation: Luminex platform supports automated operation, which can greatly reduce manual operation, lower experimental errors and improve data accuracy. In addition, automated operation can save researchers' time and energy, enabling them to focus more on experimental design and data analysis.

 


Application of Luminex platform in drug discovery:
1. Drug screening: The high-throughput detection capability of the Luminex platform makes it an ideal tool for drug screening. Researchers can utilize the platform to simultaneously detect the effects of multiple drugs on biomarkers, thereby screening for potentially efficacious drugs.
2. Efficacy assessment: The Luminex platform can accurately measure the effects of drugs in living organisms, including the effects of drugs on biomarkers and changes in cell function. These data are important for evaluating the efficacy and safety of drugs.
3. Drug monitoring: The Luminex platform can also be used to monitor the metabolism and excretion processes of drugs in organisms, as well as the potential adverse effects of drugs on organisms. This information is of great value in developing a rational medication regimen and ensuring patient safety.
Conclusion:
With its advantages of high throughput detection capability, high sensitivity, low sample requirement and high degree of automation, the Luminex platform of InnoModels Biotechnology has shown great potential in the field of drug discovery and development. The platform not only accelerates the drug screening process and improves R&D efficiency, but also provides accurate and reliable data support for drug development. In the future, with the continuous advancement of technology and the expansion of applications, the Luminex platform will play an even more important role in drug discovery and development, and make greater contributions to human health. 

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司